0001209191-20-043953.txt : 20200729
0001209191-20-043953.hdr.sgml : 20200729
20200729172958
ACCESSION NUMBER: 0001209191-20-043953
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200728
FILED AS OF DATE: 20200729
DATE AS OF CHANGE: 20200729
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novo Holdings A/S
CENTRAL INDEX KEY: 0001388325
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 201058116
BUSINESS ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
BUSINESS PHONE: 45 8824 8824
MAIL ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
FORMER NAME:
FORMER CONFORMED NAME: Novo A/S
DATE OF NAME CHANGE: 20070130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-28
0
0001693011
Inozyme Pharma, Inc.
INZY
0001388325
Novo Holdings A/S
TUBORG HAVNEVEJ 19
HELLERUP
G7
2900
DENMARK
0
0
1
0
COMMON STOCK
2020-07-28
4
C
0
2194379
A
2194379
D
COMMON STOCK
2020-07-28
4
P
0
375000
16.00
A
2569379
D
SERIES A CONVERTIBLE PREFERRED STOCK
2020-07-28
4
C
0
15000000
D
COMMON STOCK
2007225
0
D
SERIES A-2 CONVERTIBLE PREFERRED STOCK
2020-07-28
4
C
0
1398600
D
COMMON STOCK
187154
0
D
The Series A Convertible Preferred Stock and Series A-2 Convertible Preferred Stock automatically converted on a 7.4730-for-1 basis into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment or further consideration. These shares have no expiration date.
Represents a purchase from the underwriters in the Issuer's initial public offering.
Novo Holdings A/S is a Danish limited liability company. The board of directors of Novo Holdings A/S (the "Novo Board") has shared investment and voting control over the securities of the Issuer held by Novo Holdings A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.
/s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S
2020-07-29